- ICH GCP
- Amerikanska kliniska prövningsregistret
- Klinisk prövning NCT03269825
The Use of Computed Tomography (CT) to Measure Skeletal Muscle Quantity and Quality in Patients Receiving ECMO
Studieöversikt
Status
Betingelser
Detaljerad beskrivning
The use of veno-venous extra-corporeal membrane oxygenation (VV-ECMO) for severe respiratory failure - mainly hypoxaemia - has increased over recent years. Similar to the general population in the Intensive Care Unit (ICU), these patients become deconditioned, severely weak (ICU acquired weakness- ICUAW) and require prolonged rehabilitation after disconnection from VV-ECMO. However, data regarding the magnitude of muscle wasting and recovery in this specific group is lacking.
Both poor muscle quantity and quality have been found to be a predictor or poor outcome. As all patients receiving VV-ECMO at our hospital will get an initial CT scan of their chest, abdomen and pelvis, these CT scans will be used to measure muscle quantity and quality of different muscle groups of the abdomen at admission and then using any follow-up CT scan performed within 10 days. In addition, the relationship between the loss of muscle over the course of VV-ECMO and perceived recovery of renal function at ICU discharge will be investigated.
Studietyp
Inskrivning (Faktisk)
Kontakter och platser
Studieorter
-
-
-
London, Storbritannien, SE1 7EH
- Guy's and St Thomas' NHS Foundation Trust
-
-
Deltagandekriterier
Urvalskriterier
Åldrar som är berättigade till studier
Tar emot friska volontärer
Kön som är behöriga för studier
Testmetod
Studera befolkning
Beskrivning
Inclusion Criteria:
- Critically ill patients with Severe Respiratory Failure who required VV-ECMO and had one or more CT scans of their abdomen
Exclusion Criteria:
- Critically ill patients with Severe Respiratory Failure who required VV-ECMO and did not have one or more CT scans of their abdomen
- Critically ill patients with Severe Respiratory Failure who required VV-ECMO who have a poor quality CT scan not analysable by the software
Studieplan
Hur är studien utformad?
Designdetaljer
Vad mäter studien?
Primära resultatmått
Resultatmått |
Åtgärdsbeskrivning |
Tidsram |
|---|---|---|
|
All cause mortality
Tidsram: On ECMO (expected to be about 10 days)
|
Using total muscle quantity and quality measured from CT slice of the third lumbar region.
|
On ECMO (expected to be about 10 days)
|
Sekundära resultatmått
Resultatmått |
Åtgärdsbeskrivning |
Tidsram |
|---|---|---|
|
Length of ECMO duration
Tidsram: The total duration on ECMO (expected to be an average of 10 days)
|
Using total muscle quantity and quality measured from CT slice of the third lumbar region.
|
The total duration on ECMO (expected to be an average of 10 days)
|
|
Length of ICU admission
Tidsram: The total duration of ICU admission (expected to be around 2 weeks)
|
Using total muscle quantity and quality measured from CT slice of the third lumbar region.
|
The total duration of ICU admission (expected to be around 2 weeks)
|
|
Length of hospital stay
Tidsram: The total duration of hospital admission (expected to be around 28 days)
|
Using total muscle quantity and quality measured from CT slice of the third lumbar region.
|
The total duration of hospital admission (expected to be around 28 days)
|
|
Length of ventilation
Tidsram: Total duration of mechanical ventilation during intensive care unit stay (expected to be around 10 days)
|
Using total muscle quantity and quality measured from CT slice of the third lumbar region.
|
Total duration of mechanical ventilation during intensive care unit stay (expected to be around 10 days)
|
|
Discharge destination
Tidsram: After discharge from hospital (expected to be around 28 days)
|
Using total muscle quantity and quality measured from CT slice of the third lumbar region.
|
After discharge from hospital (expected to be around 28 days)
|
|
Sequential changes in the muscle quantity over time
Tidsram: The total duration of ECMO (expected to be around 10 days)
|
Using total muscle quantity measured from CT slice of the third lumbar region.
|
The total duration of ECMO (expected to be around 10 days)
|
|
Sequential changes in muscle quality over time
Tidsram: The total duration of ECMO (expected to be around 10 days)
|
Using total muscle quality measured from CT slice of the third lumbar region.
|
The total duration of ECMO (expected to be around 10 days)
|
|
Relationship between muscle loss and total nutrition received
Tidsram: The total duration of ECMO (expected to be around 10 days)
|
Using total muscle quantity measured from CT slice of the third lumbar region.
|
The total duration of ECMO (expected to be around 10 days)
|
|
Relationship between muscle loss and rehabilitation goals met
Tidsram: The total duration of ECMO (expected to be around 10 days)
|
Using total muscle quantity measured from CT slice of the third lumbar region.
|
The total duration of ECMO (expected to be around 10 days)
|
|
All cause mortality
Tidsram: Intensive Care Unit Stay (expected to be about 2 weeks)
|
Using total muscle quantity and quality measured from CT slice of the third lumbar region.
|
Intensive Care Unit Stay (expected to be about 2 weeks)
|
|
All cause mortality
Tidsram: 6 months post-ICU discharge
|
Using total muscle quantity and quality measured from CT slice of the third lumbar region.
|
6 months post-ICU discharge
|
|
All cause mortality
Tidsram: Hospital discharge (expected to be about 28 days)
|
Using total muscle quantity and quality measured from CT slice of the third lumbar region.
|
Hospital discharge (expected to be about 28 days)
|
Samarbetspartners och utredare
Utredare
- Huvudutredare: Danielle E Bear, MRes, Guy's and St Thomas' NHS Foundation Trust
Studieavstämningsdatum
Studera stora datum
Studiestart (Faktisk)
Primärt slutförande (Faktisk)
Avslutad studie (Faktisk)
Studieregistreringsdatum
Först inskickad
Först inskickad som uppfyllde QC-kriterierna
Första postat (Faktisk)
Uppdateringar av studier
Senaste uppdatering publicerad (Faktisk)
Senaste inskickade uppdateringen som uppfyllde QC-kriterierna
Senast verifierad
Mer information
Termer relaterade till denna studie
Ytterligare relevanta MeSH-villkor
Andra studie-ID-nummer
- 17/WA/0166
Plan för individuella deltagardata (IPD)
Planerar du att dela individuella deltagardata (IPD)?
Läkemedels- och apparatinformation, studiedokument
Studerar en amerikansk FDA-reglerad läkemedelsprodukt
Studerar en amerikansk FDA-reglerad produktprodukt
Denna information hämtades direkt från webbplatsen clinicaltrials.gov utan några ändringar. Om du har några önskemål om att ändra, ta bort eller uppdatera dina studieuppgifter, vänligen kontakta register@clinicaltrials.gov. Så snart en ändring har implementerats på clinicaltrials.gov, kommer denna att uppdateras automatiskt även på vår webbplats .
Kliniska prövningar på Kritisk sjukdom
-
University of AthensOkändCritical Illness Polyneuromyopati (CIPNM) | ICU Acquired Weakness (ICUAW)Grekland
-
Unity Health TorontoOkändUtbildning, Medicin | Critical Care UltrasonographyKanada
-
National Taiwan University HospitalAvslutadNeurokirurgi, Critical Ill
-
Unity Health TorontoAvslutad
-
Istituti Clinici Scientifici Maugeri SpAFondazione Don Carlo Gnocchi Onlus; Azienda Ospedaliero-Universitaria di... och andra samarbetspartnersRekryteringKritisk sjukdom Myopati | Critical Illness Polyneuromyopati (CIPNM) | Guillain Barrés syndromItalien
-
Nanjing PLA General HospitalAvslutadCritical Care Patient; Störning i nedre matsmältningskanalen; | Kolonskador;
-
Heidelberg UniversityOkändSedation av cerebrovaskulärt ventilerade Critical Care-patienterTyskland
-
National Taiwan University Clinical Trial CenterRekryteringKardiologi, Critical Care Medicine, AkutsjukvårdTaiwan